Research
Hormonal
The GLP-1 receptor agonist Semaglutide and the GIPR/GLP-1R co-agonist Tirzepatide lead to a weight loss greater than 10%.
Practitioners can consider Semaglutide and Tirzepatide as effective options for weight management in patients with obesity and Type 2 diabetes.
StrongSupportsmedium confidence
Jüngste klinische Studien belegen sowohl für den GLP-1R-Agonisten Semaglutid wie auch für den GIPR/GLP-1R-Ko-Agonisten Tirzepatide bei tolerablem Sicherheitsprofil einen Gewichtsverlust>10%.
Why this rating
Based on recent clinical studies mentioned in the abstract.
Source
GLP-1-basierte Polypharmakotherapien als wegweisender neuer Ansatz in der Behandlung von Adipositas und Diabetes
Timo D. Müller · Adipositas - Ursachen Folgeerkrankungen Therapie · 2022
DOI 10.1055/a-1904-5552
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →